Pathology Department, Faculty of Medicine, Menofiya University, Shebein Elkom.
National Cancer Institute, Cairo University, Egypt.
J Environ Pathol Toxicol Oncol. 2013;32(4):289-305. doi: 10.1615/jenvironpatholtoxicoloncol.2013007930.
Tumor-associated macrophages (TAMs) and dendritic cells (DCs) may play a role in tumor progression as a part of the tumor microenvironment in many neoplasms, including those in Hodgkin's lymphoma. The current study investigated the relationship between the presence and density of macrophages and dendritic cells in the background of classic Hodgkin's lymphoma (CHL) and different clinicopathological parameters, including survival and response to therapy. CD68 and CD1a immunohistochemical staining were used to detect and highlight macrophages and dendritic cells, respectively, in 61 cases of CHL. CD68 was expressed in all studied cases, with no significant association with the studied parameters. In total, 54.1% (33/61) of cases showed CD1a expression. High CD1a expression (>7%) was associated with localized lymphadenopathy (p=0.01), early stage (p=0.005), and good revised international prognostic index (R-IPI) (p=0.07). Hodgkin's lymphoma cases that showed high CD68 and low CD1a were associated with adverse prognostic parameters such as advanced stage (p=0.03) and generalized lymphadenopathy (p=0.05). Old age (>60 years) (P=0.005), poor R-IPI (P=0.010), and negative CD1a expression (P=0.045) were significantly associated with poor outcome. Finally, our study demonstrated the importance of the presence and density of DCs in determining progression and prognosis in CHL. A certain interaction between TAMs and DCs may affect the progression of CHL. Further investigation is required to clarify whether TAMs release certain factors that decrease the number or function of DCs.
肿瘤相关巨噬细胞（TAMs）和树突状细胞（DCs）可能在许多肿瘤中作为肿瘤微环境的一部分，在肿瘤进展中发挥作用，包括霍奇金淋巴瘤。本研究探讨了经典霍奇金淋巴瘤（CHL）背景中巨噬细胞和树突状细胞的存在和密度与不同临床病理参数之间的关系，包括生存和对治疗的反应。使用 CD68 和 CD1a 免疫组织化学染色分别检测和突出显示巨噬细胞和树突状细胞，共检测了 61 例 CHL。所有研究病例均表达 CD68，与研究参数无显著相关性。总共，54.1%（33/61）的病例显示 CD1a 表达。高 CD1a 表达（>7%）与局部淋巴结病（p=0.01）、早期（p=0.005）和良好的修订国际预后指数（R-IPI）（p=0.07）相关。表现为高 CD68 和低 CD1a 的霍奇金淋巴瘤病例与不良预后参数相关，如晚期（p=0.03）和全身性淋巴结病（p=0.05）。老年（>60 岁）（P=0.005）、不良的 R-IPI（P=0.010）和阴性 CD1a 表达（P=0.045）与不良结局显著相关。最后，我们的研究表明了 DCs 的存在和密度在确定 CHL 的进展和预后中的重要性。TAMs 和 DCs 之间的一定相互作用可能会影响 CHL 的进展。需要进一步研究来阐明 TAMs 是否释放某些因素，导致 DCs 的数量或功能减少。
